NCT03377192

Brief Summary

This study evaluates the value of impedance pneumography, used as overnight home recordings during a longitudinal design, in assessing asthma control in preschool children

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2017

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 28, 2017

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

December 5, 2017

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 19, 2017

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 14, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2020

Completed
Last Updated

February 13, 2020

Status Verified

February 1, 2020

Enrollment Period

2 years

First QC Date

December 5, 2017

Last Update Submit

February 12, 2020

Conditions

Keywords

Impedance pneumographyRespiratory functionAsthma management

Outcome Measures

Primary Outcomes (1)

  • Childhood asthma control test (C-ACT)

    Questionnaire that measures current asthma control, including 7 questions and a minimum score of 0 and maximum score of 27; score 19 or less indicates that asthma is not controlled.

    Weekly up to maximum 6 months or until loss of asthma control/exacerbation

Secondary Outcomes (3)

  • Time-to-response (TTR)

    Minimum of 30 days from initiation of anti-asthmatic medication up to max 6 months

  • Time-to-loss-of-control (TTLOC)

    Minimum of 30 days from initiation of anti-asthmatic medication up to max 6 months

  • Lung function

    Every visit up to maximum 6 months

Eligibility Criteria

Age4 Years - 7 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Thirty (30) patients who have attended pediatric ward in the study centre(s) due to asthmatic symptoms (wheeze, cough, dyspnea) will be recruited.

You may qualify if:

  • Age 4-7 years, both sexes
  • Attending pediatric ward in the study centre due to asthmatic symptoms (wheeze, cough and/or dyspnea)
  • History and clinical signs allowing diagnosis of doctor diagnosed asthma and the need to start regular anti-asthmatic medication
  • Signed informed consent

You may not qualify if:

  • Use of inhaled corticosteroid medication 30 days prior to study entry
  • Other cardiorespiratory or neurological chronic diseases or states that may affect breathing
  • Acute respiratory infection 2 weeks prior to study entry
  • Chronic respiratory disorder of prematurity
  • Implanted or external active medical devices

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

HUS Skin and Allergy Hospital

Helsinki, 00029, Finland

Location

Mehiläinen Paediatric Allergy Clinic

Helsinki, 00260, Finland

Location

Related Publications (1)

  • Burman J, Malmberg LP, Remes S, Jartti T, Pelkonen AS, Makela MJ. Impulse oscillometry and free-running tests for diagnosing asthma and monitoring lung function in young children. Ann Allergy Asthma Immunol. 2021 Sep;127(3):326-333. doi: 10.1016/j.anai.2021.03.030. Epub 2021 Apr 2.

MeSH Terms

Conditions

Respiratory SoundsRespiratory Aspiration

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsRespiration DisordersRespiratory Tract DiseasesPathologic Processes

Study Officials

  • Pekka Malmberg, MD, PhD

    HUS Skin and Allergy Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of clinical physiology

Study Record Dates

First Submitted

December 5, 2017

First Posted

December 19, 2017

Study Start

November 28, 2017

Primary Completion

November 14, 2019

Study Completion

June 1, 2020

Last Updated

February 13, 2020

Record last verified: 2020-02

Locations